Keyphrases
Denmark
100%
Type 2 Diabetes Mellitus (T2DM)
50%
Confidence Interval
38%
Clinical Outcomes
33%
Small-for-gestational Age
32%
National Cohort Study
30%
Glucose-lowering Drugs
28%
Sweden
25%
Duloxetine
25%
Psoriasis
25%
Adverse Pregnancy Outcomes
25%
Healthcare Resource Utilization
25%
Medication Use
24%
Danish Registry
21%
Stillbirth
19%
Odds Ratio
19%
Adjusted Hazard Ratio
19%
Congenital Malformations
17%
Hazard Ratio
16%
COVID-19
15%
National Registry
15%
Capital Region
15%
Danish National Patient Registry
14%
Hemoglobin A1c (HbA1c)
14%
Major Depressive Disorder
14%
During Pregnancy
14%
Preterm Birth
14%
Type 2 Diabetic Patients
14%
Pharmacological Treatment
14%
Case-time-control
12%
Neurological Events
12%
Singleton
12%
Health-related Quality of Life
12%
Thromboembolic Complications
12%
Randomized Controlled Trial
12%
Hypercholesterolemia
12%
Arthroplasty Register
12%
Patients with COVID-19
12%
Mortality Outcomes
12%
Bleeding Complications
12%
Knee Arthroplasty
12%
Glycemic Control
12%
KRAS G12C
12%
Metronidazole
12%
Primary Total Knee Arthroplasty
12%
Medical Patients
12%
Diabetes Control
12%
Hip Arthroplasty
12%
Safety Study
12%
Malnutrition
12%
Atherosclerotic Cardiovascular Disease (ASCVD)
12%
Age Disparity
12%
Intervention Group
12%
Matched Cohort Study
12%
Low-density Lipoprotein Cholesterol (LDL-C)
12%
Hospitalized Patients
12%
Thromboprophylaxis
12%
Cardiovascular Disease Events
12%
Low Molecular Weight Heparin
12%
Nutritional Intervention
12%
Malnutrition Risk
12%
Time Use
12%
Validation Studies
12%
In Utero Exposure
12%
Gestational Diabetes
12%
Register Study
12%
Vitamin D
12%
Treatment Patterns
12%
Registry Study
12%
Poisoning
12%
Overall Survival
12%
Living with
12%
Short-term Mortality
12%
Sulfonylurea
12%
Treatment-resistant
12%
Food Fortification
12%
Tramadol
12%
Registry-based
12%
Psychiatric Treatment
12%
Cystic Fibrosis
12%
Pharmacoepidemiology
12%
Cancer Characteristics
12%
Suicide Attempt
12%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
12%
Suicide Death
12%
Treatment-resistant Depression
12%
Diabetes
12%
Adverse Events
12%
Rational Pharmacotherapy
12%
Modified Electroconvulsive Therapy
12%
Polypharmacy
12%
Positive Predictive Value
11%
Comorbidity
10%
Ectopic Pregnancy
10%
Hospitalization
10%
30-day Mortality
10%
Dalteparin
10%
Rivaroxaban
10%
Dabigatran
10%
Hospital Contacts
9%
Medicine and Dentistry
Drug Therapy
45%
Cohort Analysis
40%
Maturity Onset Diabetes of the Young
37%
Health Care Cost
27%
COVID-19
25%
Psoriasis
25%
Diabetes
16%
Stillbirth
13%
Patient Registry
13%
Glycemic Control
12%
Randomized Controlled Trial
12%
Hypercholesterolemia
12%
Congenital Malformation
12%
Metronidazole
12%
Premature Labor
12%
Cross Sectional Study
12%
Intensive Care Unit
12%
Knee Arthroplasty
12%
Drug Safety
12%
Nutritional Intervention
12%
Overall Survival
12%
Cystic Fibrosis
12%
Hip Arthroplasty
12%
Sulfonylurea
12%
Duloxetine
12%
Quality of Life
12%
Small for Gestational Age
12%
Case-Control Study
12%
Low Molecular Weight Heparin
12%
Low Density Lipoprotein Cholesterol
12%
Anticoagulation
12%
Non Small Cell Lung Cancer
12%
Adverse Event
12%
Electroconvulsive Therapy
12%
Hazard Ratio
9%
Odds Ratio
9%
Childbirth
8%
Glucagon-Like Peptide-1 Agonist
8%
Patient with Type 2 Diabetes
8%
Programmed Death-Ligand 1
8%
Sodium Glucose Cotransporter 2 Inhibitor
8%
Hypoglycemia
8%
Body Weight
7%
Wellbeing
7%
Muscle Strength
7%
Antibiotic Therapy
7%
Antithrombotic
7%
Ectopic Pregnancy
6%
Disease
6%
Drug Exposure
6%
Cardiovascular System
6%
Prevalence
5%
Protein Intake
5%
Pharmacology, Toxicology and Pharmaceutical Science
Cohort Study
55%
Non Insulin Dependent Diabetes Mellitus
37%
Duloxetine
25%
Congenital Malformation
25%
Patient Registry
25%
Small for Date Infant
20%
Stillbirth
18%
Major Depression
14%
Adverse Event
14%
Coronary Artery Atherosclerosis
12%
Non Small Cell Lung Cancer
12%
Drug Safety
12%
Overall Survival
12%
Thromboembolism
12%
Metronidazole
12%
Hypercholesterolemia
12%
Treatment Resistant Depression
12%
Vitamin D
12%
Sulfonylurea
12%
Pregnancy Diabetes Mellitus
12%
Dalteparin
12%
Cystic Fibrosis
12%
Dabigatran
12%
Rivaroxaban
12%
Tramadol
12%
Low Molecular Weight Heparin
12%
Bleeding
12%
Low Density Lipoprotein Cholesterol
12%
Cross-Sectional Study
12%
Toxic Injury
12%
Pharmacotherapy
12%
Non Insulin Dependent Diabetes Mellitus
12%
Schizoaffective Psychosis
12%
Polypharmacy
12%
Venous Thromboembolism
11%
Hypoglycemia
9%
Glucagon Like Peptide 1 Receptor Agonist
8%
Sodium Glucose Cotransporter 2 Inhibitor
8%
Prevalence
6%
All Cause Mortality
6%
Disease
6%
Comorbidity
5%